Clinical Trials

Research Improves Outcomes

Dana-Farber Research

Nearly all cancer drugs in use today were once tested and made available to patients through clinical trials. Patients who choose to participate in a trial receive the most advanced cancer treatment available, sometimes years before it’s offered anywhere else.

As a leader in advancing cancer care, Dana-Farber Cancer Institute offers hundreds of clinical trials aimed at improving outcomes and reducing side effects. Patients have access to clinical trials through Dana-Farber/Harvard Cancer Center, a nationally designated Comprehensive Cancer Center. In addition to the full portfolio of clinical trials in Boston, we are pleased to offer many select trials right here in our South Weymouth location at Dana-Farber/Brigham Cancer Center at South Shore Health.

Our local select trials include those for patients with breast, colon, esophageal, gastric, gynecologic, lung, prostate or rectal cancer, which allows innovative treatment accessibility to the South Shore region.

Entering a clinical trial: Is it right for you?

By participating in a clinical trial, patients may not only benefit from a new leading-edge cancer treatment, but will also be advancing medicine and potentially helping others who are diagnosed with cancer for generations to come.

See the list of open trials below, which are subject to updates. Visit the Dana Farber site to learn more about the latest trials currently being offered and whether entering a clinical research trial is right for you. 

Currently Open Clinical Trials at the Dana Farber Cancer Center

DCFI #20-166: A randomized phase II study of sacituzumab govitecan +/-pembrolizumab in PD-L1 negative metastatic TNBC

DCFI #20-347: A Single Arm Phase II study of Adjuvant Endocrine Therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic Stage I hormone-receptor positive, Her-2 positive breast cancer

DCFI #21-560: THE COMPASS HER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB

DCFI #21-159: A Randomized Phase II trial of adjuvant TDM1 followed by SC Trastuzumab vs. Pacliatel in combination with SC Trastuzumab for Stage I Her2 positive breast cancer

DCFI #22-680: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

DCFI #22-655: "The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer

DCFI #23-531: SATEEN - A single-arm phase II trial of SAcituzumab govitecan and Trastuzumab for HER2+ metastatic breast cancer after progrEssion on ENhertu

DCFI #22-296: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)

DCFI #23-051: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

DCFI #20-379: Integration of Immunotherpy into Adjuvant Therapy for Resected NSCLC

DCFI #21-244: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab plus Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

DCFI #**20-484: MRI BRAIN SURVEILLANCE ALONE VERSUS MRI SURVEILLANCE AND PROPHYLACTIC CRANIAL IRRADIATION (PCI): A RANDOMIZED PHASE III TRIAL IN SMALL-CELL LUNG CANCER (MAVERICK)

DCFI #23-081: RANDOMIZED PHASE III TRIAL OF MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB FOR FIRST-LINE TREATMENT OF METASTATIC HER2-NEGATIVE GASTROESOPHAGEAL ADENOCARCINOMA

DCFI #23-377: The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

DCFI #22-709: COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

DCFI #**21-191: Risk-adapted therapy in low-risk HPV+ oropharyngeal cancer using circulating tumor (ct)HPV DNA profile | The ReACT Study

DCFI #21-507: A Randomized Phase II Study Comparing Sequential High dose Testosterone and Enzalutamide to Enzalutamide alone in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The STEP-UP Trial (Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression)

DCFI #24-138: MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRD-BASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL CANCER

DCFI #22-335: A Randomized Phase II Study of Androgen Receptor Directed Therapy on COGnitive Function in Patients Treated with Darolutamide or Enzalutamide 

DCFI #**21-031: PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)

DCFI #23-695: Phase 2, randomized, trial of maintenance Letrozole/Abemaciclib vs Pembrolizumab after systemic therapy in patients with advanced or recurrent estrogen receptor positive, mismatch repair proficient, TP53 wild-type endometrial cancer 

DCFI #21-279: A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL/SLL Patients

DCFI #24-017: A phase 2 study of fixed duration therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)

DCFI #**19-192: Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone metastases from Multiple Myeloma (10/4/22-possibly closing soon)

DCFI #18-617: A prospective registry to cure TNBC in patients with early stage or newly diagnosed metastatic disease: VICTORY

DCFI #21-169: Assessing the Impact of Scalp Cooling in Patients with Metastatic Breast Cancer

DCFI #14-174:   Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome

DCFI #15-700:   Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

DCFI #01-045: COLLECTION OF SPECIMENS AND CLINICAL DATA FOR PATIENTS WITH PROSTATE CANCER OR AT HIGH RISK FOR PROSTATE CANCER

DCFI #19-081: A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy

DCFI #18-420: Chronic Lymphocytic Leukemia (CLL) Collaborative Study Of Real-World Evidence (CORE)

DCFI #21-508: Video Education with Result Dependent dIsclosure (VERDI)

DCFI #**20-567: Prospective evaluation of patient-reported pain response and comparison to international consensus guidelines in patients receiving palliative radiation for bone metastases

DCFI #**18-614: Evaluation of Quality of Life Issues Among Patients Receiving SBRT for Non-Organ Soft Tissue and Bone Metastases

DCFI #**20-387: Prospective serial registry to evaluate outcomes after stereotactic radiotherapy in patients with brain metastases

DCFI #**18-627: Prospective evaluation of overall and symptomatic quality of life among patients receiving radiation therapy for symptomatic leptomeningeal disease of the brain or spine